目的 分析卡瑞利珠單抗致藥物不良反應(yīng)（ADR）發(fā)生的臨床特點及規(guī)律，為臨床合理用藥提供參考。方法 檢索國內(nèi)外數(shù)據(jù)庫（截至2022年3月1日）關(guān)于卡瑞利珠單抗致ADR的文獻(xiàn)報道，提取數(shù)據(jù)并進(jìn)行分析。結(jié)果 卡瑞利珠單抗致ADR個案報道15篇，涉及患者17例，其中男性12例，女性5例，ADR發(fā)生年齡多分布在50～79歲（13例，76.47%），且多發(fā)生在用藥后30 d內(nèi)（9例，52.94%）。卡瑞利珠單抗致ADR主要以皮膚及其附件損害較多（9例，52.94%），14例經(jīng)停藥和（或）對癥治療后好轉(zhuǎn)或痊愈。結(jié)論 卡瑞利珠單抗致ADR涉及多個年齡段患者，累及多個系統(tǒng)/器官，尤其是皮膚及其附件損害較多，需引起高度重視，臨床使用時需加強用藥監(jiān)測，綜合評估患者利益風(fēng)險，及早識別藥品ADR，及時進(jìn)行臨床處理。

Objective To analyze the clinical characteristics and regularity of adverse drug reaction induced by camrelizumab in order to provide references for rational drug use in clinic. Methods Literature reports of ADR induced by camrelizumab were retrieved from the databases at home and abroad (as of March 1, 2022), and the data were extracted and analyzed. Results There were 15 reported cases of ADR induced by camrelizumab, involving 17 patients, including 12 males and 5 females, mainly aged between 50 and 79 years old (13 cases, 76.47%). Most cases occurred within 30 d after drug administration (9 cases, 52.94%). Skin and accessory damage was the most common primary disease (9 cases, 52.94%). 14 Cases were improved or recovered after drug withdrawal and/or symptomatic treatment. Conclusion ADR caused by carrilizumab involves patients of multiple ages and involves multiple systems/organs, especially skin and its accessories, which requires high attention. Drug monitoring should be strengthened during clinical use, comprehensive assessment of patients' interests and risks, early identification of drug ADR, and timely clinical treatment.

R979.1